ENTITY

Faron Pharmaceuticals Oy (FARN LN)

Analysis

Health Care • Finland

Faron Pharmaceuticals Oy operates as a drug discovery and development company in Finland. It has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy, and vascular damage. The company?s lead product candidate includes Traumakine, a recombinant human IFN beta-1a, which is Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It is also developing Clevegen, a pre-clinical immunotherapy candidate, designed to prevent tumor growth and metastasis which targets the tumor immune suppressor molecule; Farbetic, an AOC3 inhibitor, for use in the prevention of vascular deformations in various disease conditions, such as diabetes; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. The company was founded in 2003 and is based in Turku, Finland. Faron Pharmaceuticals Oy is a subsidiary of Faron Ventures Oy.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now